US20130053551A1 - Cation and anion exchange chromatography method - Google Patents
Cation and anion exchange chromatography method Download PDFInfo
- Publication number
- US20130053551A1 US20130053551A1 US13/588,281 US201213588281A US2013053551A1 US 20130053551 A1 US20130053551 A1 US 20130053551A1 US 201213588281 A US201213588281 A US 201213588281A US 2013053551 A1 US2013053551 A1 US 2013053551A1
- Authority
- US
- United States
- Prior art keywords
- exchange chromatography
- chromatography material
- polypeptide
- ion exchange
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
- B01D15/361—Ion-exchange
- B01D15/362—Cation-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
- B01D15/361—Ion-exchange
- B01D15/363—Anion-exchange
Definitions
- prokaryotic cells such as E. coli
- mammalian cells such as CHO cells, NS0 cells, Sp2/0 cells, COS cells, HEK cells, BHK cells, PER.C6® cells, and the like.
- affinity chromatography with microbial proteins e.g. protein A or protein G affinity chromatography
- ion exchange chromatography e.g. cation exchange (sulfopropyl or carboxymethyl resins), anion exchange (amino ethyl resins) and mixed-mode ion exchange
- thiophilic adsorption e.g. with beta-mercaptoethanol and other SH ligands
- hydrophobic interaction or aromatic adsorption chromatography e.g. with phenyl-sepharose, aza-arenophilic resins, or m-aminophenylboronic acid
- metal chelate affinity chromatography e.g.
- Ni(II)- and Cu(II)-affinity material size exclusion chromatography
- electrophoretical methods such as gel electrophoresis, capillary electrophoresis
- Vijayalakshmi M. A., Appl. Biochem. Biotech. 75 (1998) 93-102).
- Necina, R., et al. (Biotechnol. Bioeng. 60 (1998) 689-698) reported the capture of human monoclonal antibodies directly from cell culture supernatants by ion exchange media exhibiting high charge density.
- WO 89/05157 a method is reported for the purification of product immunoglobulins by directly subjecting the cell culture medium to a cation exchange treatment.
- a polypeptide can be recovered from an ion exchange chromatography material (cation and/or anion exchange chromatography material) with a solution comprising a denaturant/chaotropic agent, whereby during the recovering of the polypeptide from the ion exchange chromatography material the conductivity of the applied solutions is maintained constant, i.e. the conductivity is kept constant.
- One aspect as reported herein is a method for obtaining or purifying a polypeptide by ion exchange chromatography in bind-and-elute mode comprising the following step:
- the first ion exchange chromatography material is an anion exchange chromatography material and the second ion exchange chromatography material is a cation exchange chromatography material.
- the first ion exchange chromatography material is a cation exchange chromatography material and the second ion exchange chromatography material is an anion exchange chromatography material.
- the denaturant is urea or a urea-derivative.
- the denaturant is a mixture of two or three denaturants.
- the solution applied in the recovering has a constant conductivity.
- the solution applied in the wash step has a constant conductivity.
- the solution applied in the recovering has a constant pH-value.
- the solution applied in the wash step has a constant pH-value.
- the ion exchange chromatography material is a cation exchange chromatography material.
- the ligand is sulfopropyl or carboxymethyl.
- the ion exchange chromatography material is an anion exchange chromatography material.
- the ligand is poly ethyleneimine or quaternized ethyleneimine.
- polypeptide is an antibody, or an antibody fragment, or a fusion polypeptide comprising at least one antibody domain.
- polypeptide is a tetranectin-apolipoprotein A-I fusion protein.
- tetranectin-apolipoprotein A-I fusion protein has an amino acid sequence of SEQ ID NO: 01, or SEQ ID NO: 02, or SEQ ID NO: 03, or SEQ ID NO: 04.
- One aspect as reported herein is a method for producing a polypeptide comprising the following steps:
- FIG. 1 Chromatogram of a purification of tetranectin-apolipoprotein A-I fusion protein of SEQ ID NO: 01 on an anion exchange chromatography column with sodium chloride conductivity gradient.
- FIG. 2 Chromatogram of a purification of tetranectin-apolipoprotein A-I fusion protein of SEQ ID NO: 01 on an anion exchange chromatography column with urea gradient at constant conductivity and constant pH-value.
- FIG. 3 Chromatogram of a purification of tetranectin-apolipoprotein A-I fusion protein of SEQ ID NO: 02 on an anion exchange chromatography column with urea gradient at constant conductivity and constant pH-value.
- FIG. 4 Chromatogram of a purification of tetranectin-apolipoprotein A-I fusion protein of SEQ ID NO: 01 on an anion exchange chromatography column with urea wash, isopropanol wash and guanidinium hydrochloride gradient elution.
- FIG. 5 Chromatogram of a purification of tetranectin-apolipoprotein A-I fusion protein of SEQ ID NO: 01 on an anion exchange chromatography column with urea wash, guanidinium hydrochloride wash and sodium chloride gradient elution.
- FIG. 6 Chromatogram of a purification of tetranectin-apolipoprotein A-I fusion protein of SEQ ID NO: 02 on an anion exchange chromatography column with urea wash, guanidinium hydrochloride wash and sodium chloride gradient elution.
- FIG. 7 Chromatogram of a purification of tetranectin-apolipoprotein A-I fusion protein of SEQ ID NO: 01 on a cation exchange chromatography column with urea gradient at constant conductivity and constant pH-value.
- FIG. 8 Chromatogram of a purification of anti-TSLP receptor antibody on an anion exchange chromatography column with Tris buffer wash and urea gradient elution.
- the terms “applying to” and grammatical equivalents thereof denote a partial step of a purification method in which a solution containing a substance of interest to be purified is brought in contact with a stationary phase.
- a solution is added to a chromatographic device in which the stationary phase is located, or b) that a stationary phase is added to the solution comprising the substance of interest.
- the solution containing the substance of interest to be purified passes through the stationary phase allowing for an interaction between the stationary phase and the substances in solution.
- some substances of the solution are bound to the stationary phase and, thus, are removed from the solution.
- the “flow-through” denotes the solution obtained after the passage of the chromatographic device irrespective of its origin. It can either be the applied solution containing the substance of interest or the buffer, which is used to flush the column or which is used to cause the elution of one or more substances bound to the stationary phase.
- the chromatographic device is a column, or a cassette.
- the substance of interest can be recovered from the solution after the purification step by methods familiar to a person of skill in the art, such as e.g. precipitation, salting out, ultrafiltration, diafiltration, lyophilization, affinity chromatography, or solvent volume reduction to obtain the substance of interest in purified or even substantially homogeneous form.
- the stationary phase is added, e.g. as a solid, to the solution containing the substance of interest to be purified allowing for an interaction between the stationary phase and the substances in solution. After the interaction the stationary phase is removed, e.g. by filtration, and the substance of interest is either bound to the stationary phase and removed therewith from the solution or the substance of interest is not bound to the stationary phase and remains in the solution.
- buffered denotes a solution in which changes of pH due to the addition or release of acidic or basic substances is leveled by a buffer substance. Any buffer substance resulting in such an effect can be used.
- the buffer substance is selected from phosphoric acid or salts thereof, acetic acid or salts thereof, citric acid or salts thereof, morpholine, 2-(N-morpholino) ethanesulfonic acid or salts thereof, imidazole or salts thereof, histidine or salts thereof, glycine or salts thereof, or tris (hydroxymethyl) aminomethane (TRIS) or salts thereof.
- the buffer substance is selected from imidazole or salt thereof or histidine or salts thereof.
- the buffered solution may also comprise an additional inorganic salt.
- the inorganic salt is selected from sodium chloride, sodium sulphate, potassium chloride, potassium sulfate, sodium citrate, and potassium citrate.
- polypeptide is a polymer consisting of amino acids joined by peptide bonds, whether produced naturally or synthetically. Polypeptides of less than about 20 amino acid residues may be referred to as “peptides”, whereas molecules consisting of two or more polypeptides or comprising one polypeptide of more than 100 amino acid residues may be referred to as “proteins”.
- a polypeptide may also comprise non-amino acid components, such as carbohydrate groups, metal ions, or carboxylic acid esters. The non-amino acid components may be added by the cell, in which the polypeptide is expressed, and may vary with the type of cell. Polypeptides are defined herein in terms of their amino acid backbone structure or the nucleic acid encoding the same. Additions such as carbohydrate groups are generally not specified, but may be present nonetheless.
- antibody denotes a protein that comprises at least two light polypeptide chains and two heavy polypeptide chains.
- Each of the heavy and light polypeptide chains contains a variable region (generally the amino terminal portion of the polypeptide chain) which contains a binding domain for interaction with the antigen.
- Each of the heavy and light polypeptide chains also comprises a constant region (generally the carboxyl terminal portion) which may mediate the binding of the antibody to host tissues or factors including various cells of the immune system, some phagocytic cells and a first component (C1q) of the classical complement system.
- the light and heavy polypeptide chains are complete chains, each consisting essentially of a variable region, i.e.
- variable regions of the antibody according to the invention can be grafted to constant regions of other isotypes.
- a polynucleotide encoding the variable region of a heavy chain of the 1-isotype can be grafted to polynucleotide encoding the constant region of another heavy chain class (or subclass).
- Antibodies may exist in a variety of forms, including, for example, Fv, Fab, and F(ab) 2 as well as single chains (e.g. Huston, J. S., et al., Proc. Natl. Acad. Sci. USA 85 (1988) 5879-5883; Bird, R. E., et al., Science 242 (1988) 423-426; and, in general, Hood, et al., Immunology, Benjamin N.Y., 2nd edition, The Benjamin/Cummings Publishing Company, Inc. (1984), and Hunkapiller, T. and Hood, L., Nature 323 (1986) 15-16).
- the antibody is selected from monoclonal antibody, isolated heavy or light chain, or heavy or light chains only consisting of constant regions as well as fragments thereof.
- the term “constant” denotes that a certain value is maintained at a level with a relative change of at most 10%.
- the conductivity of the solution in the recovering step is maintained constant with a change of at most +/ ⁇ 10%. In one embodiment the conductivity of the solution in the recovering step is maintained constant with a change of at most +/ ⁇ 5%. In one embodiment the conductivity of the solution in the recovering step is maintained constant with a change of at most +/ ⁇ 2%.
- binding-and-elute mode denotes a way to perform a chromatography purification method.
- a solution containing a polypeptide of interest to be purified is applied to a stationary phase, particularly a solid phase, whereby the polypeptide of interest interacts with the stationary phase and is retained thereon. Substances not of interest are removed with the flow-through or the supernatant, respectively.
- the polypeptide of interest is afterwards recovered from the stationary phase in a second step by applying an elution solution.
- inclusion body denotes a dense intracellular mass of aggregated polypeptide of interest, which constitutes a significant portion of the total cell protein, including all cell components of a prokaryotic cell.
- polypeptides denotes forms of polypeptides wherein these have a secondary, tertiary, and/or quaternary structure that is not the native one.
- the polypeptide in this non-native form may be soluble but concomitantly in a biologically inactive conformation. Or the polypeptide may be insoluble and in a biologically inactive conformation with e.g. mismatched or unformed disulfide bonds. This insoluble polypeptide can be, but need not be, contained in inclusion bodies.
- refolded refers to a polypeptide obtained from a denaturized form. Typically, the goal of refolding is to produce a protein having a higher level of activity than the protein would have if produced without a refolding step.
- a folded protein molecule is most stable in the conformation that has the least free energy. Most water soluble proteins fold in a way that most of the hydrophobic amino acids are in the interior part of the molecule, away from water. The weak bonds that hold a protein together can be disrupted by a number of treatments that cause a polypeptide to unfold, i.e. to denaturize.
- a folded protein is the product of several types of interactions between the amino acids themselves and their environment, including ionic bonds, Van der Waals interactions, hydrogen bonds, disulfide bonds and covalent bonds.
- denatured or “denaturized” as used herein refer to a polypeptide in which ionic and covalent bonds and Van der Waals interactions which exist in the molecule in its native or refolded state are disrupted. Denaturation of a polypeptide can be accomplished, for example, by treatment with 8 M urea, reducing agents such as mercaptoethanol, heat, pH, temperature and other chemicals. Reagents such as 8 M urea disrupt both the hydrogen bonds and the hydrophobic bonds, and if mercaptoethanol is also added, the disulfide bridges (S—S) which are formed between cysteines are reduced to two —S—H groups. Refolding of polypeptides which contain disulfide linkages in their native or refolded state may also involve the oxidation of the —S—H groups present on cysteine residues for the protein to reform the disulfide bonds.
- chaotropic agent or “denaturant”, which can be used interchangeably, denotes a compound that distorts the three-dimensional structure of a polypeptide. This process is also called denaturation.
- the chaotropic agent distorts/disrupts interactions by non-covalent forces such as hydrogen bonds, or van der Waals forces.
- the chaotropic agent is selected from the group comprising butanol, ethanol, 1- and 2-propanol, guanidinium chloride, magnesium chloride, sodium dodecyl/sodium lauryl sulfate, urea, and thiourea.
- in native form denotes the form of a polypeptide wherein it has a secondary, tertiary, and/or quaternary structure in which the polypeptide has his biological activity.
- the term “ion exchange chromatography material” denotes an immobile high molecular weight matrix that carries covalently bound charged substituents. For overall charge neutrality not covalently bound counter ions are bound to the charged substituents by ionic interaction.
- the “ion exchange chromatography material” has the ability to exchange its not covalently bound counter ions for similarly charged binding partners or ions of the surrounding solution.
- the “ion exchange chromatography material” is referred to as “cation exchange chromatography material” or as “anion exchange chromatography material”.
- the “ion exchange chromatography material” is referred to as, e.g.
- the “ion exchange chromatography material” can additionally be classified as strong or weak ion exchange material, depending on the strength of the covalently bound charged substituent.
- strong cation exchange materials have a sulfonic acid group, such as a sulfopropyl group, as charged substituent
- weak cation exchange materials have a carboxylic acid group, such as a carboxymethyl group, as charged substituent.
- Strong anion exchange materials have a quarternary ammonium group
- weak anion exchange materials have a diethylaminoethyl group as charged substituent.
- the position of an ion exchange chromatography step is variable in a multi-step purification sequence of a polypeptide.
- Methods for purifying polypeptides are well established and widespread used. They are employed either alone or in combination. Such methods are, for example, affinity chromatography using thiol ligands with complexed metal ions (e.g. with Ni(II)- and Cu(II)-affinity material) or microbial-derived proteins (e.g. protein A or protein G affinity chromatography), ion exchange chromatography (e.g. cation exchange (carboxymethyl resins), anion exchange (amino ethyl resins) and mixed-mode exchange chromatography), thiophilic adsorption (e.g. with beta-mercaptoethanol and other SH ligands), hydrophobic interaction or aromatic adsorption chromatography (e.g.
- the purification process of immunoglobulins in general comprises a multistep chromatographic part.
- non-immunoglobulin polypeptides and proteins are separated from the immunoglobulin fraction by an affinity chromatography, e.g. with protein A.
- an ion exchange chromatography can be performed.
- a third chromatographic step can be performed to separate immunoglobulin monomers from multimers and fragments of the same class.
- the amount of aggregates is high (5% or more) and it is not possible to separate them efficiently in the third purification step necessitating further purification steps.
- a polypeptide can be recovered from an ion exchange chromatography material, which comprises a matrix of cross-linked poly (styrene-divinylbenzene) to which ionic ligands have been attached, with a solution comprising a denaturant, whereby the conductivity of the solution is kept constant during the recovering.
- ion exchange chromatography material which comprises a matrix of cross-linked poly (styrene-divinylbenzene) to which ionic ligands have been attached, with a solution comprising a denaturant, whereby the conductivity of the solution is kept constant during the recovering.
- one aspect as reported herein is a method for obtaining or purifying a polypeptide comprising the following step:
- the solution comprising the polypeptide which is applied to the ion exchange chromatography material is free of denaturants.
- the polypeptide retained on the ion exchange chromatography material is recovered with a solution comprising a denaturant such as urea or a urea-derivative and a constant conductivity.
- the method as reported herein is, thus, operated in bind-and-elute mode, i.e. the polypeptide is first bound to the ion exchange chromatography material and thereafter, in a further step, recovered from the ion exchange chromatography material. Intermittent wash steps can be included in the methods as reported herein.
- the applied solution(s) is (are) substantially free of a denaturant.
- substantially free of a denaturant denotes that a denaturant can be present in the applied (wash) solution but at a concentration that is below the concentration required for the recovery of the polypeptide from the ion exchange material.
- the solution comprising the denaturant is an aqueous solution.
- the solution comprising the denaturant does not comprise, i.e. it is free of, an organic solvent and/or an aliphatic alcohol.
- the solution comprising the denaturant is consisting of water, the denaturant, a buffer substance, and optionally one or two or three inorganic salts.
- denaturant or “chaotropic agent”, which can be used interchangeably within this application, denotes compounds that transfer a polypeptide from its native form in a non-native, i.e. denatured, form.
- Denaturants are generally chaotropic agents.
- Exemplary denaturants are urea and urea-derivatives, guanidine and guanidine-derivatives, tetraalkyl ammonium salts, long chain sulfonic acid esters, and lithium perchlorate.
- the change of the concentration of urea does not affect the conductivity of a solution, i.e. the conductivity of a solution remains constant upon the addition or change of the concentration of urea.
- the denaturant is urea or a urea-derivative.
- the denaturant is urea. In one embodiment the urea has a concentration of from 4 mol/l to 9 mol/l.
- the denaturant is thiourea. In one embodiment the thiourea has a concentration of from 1.5 mol/l to 3 mol/l.
- the denaturant is a mixture of two or three denaturants. In one embodiment the denaturant is a mixture of urea and thiourea. In one embodiment the denaturant is a mixture of urea and a guanidinium salt.
- the first and second solutions are substantially free of a denaturant.
- the third solution is substantially free of a denaturant.
- Polypeptides can be produced recombinantly in eukaryotic and prokaryotic cells, such as CHO cells, HEK cells and E. coli . If the polypeptide is produced in prokaryotic cells it is generally obtained in the form of insoluble inclusion bodies. The inclusion bodies can easily be recovered from the prokaryotic cell and the cultivation medium. The polypeptide obtained in insoluble form in the inclusion bodies has to be solubilized before purification and/or re-folding procedure can be carried out.
- a second aspect as reported herein is a method for producing a polypeptide comprising the following steps:
- the first solution comprises a first buffer substance
- the second solution comprises a second buffer substance
- the third solution comprises a third buffer substance
- the fourth solution comprises a fourth buffer substance, whereby the fourth buffer substance comprises one or more denaturants.
- the second buffer substance and the third buffer substance and the fourth buffer substance are all different buffer substances.
- first solution and/or the second solution and/or the third solution is/are free of a denaturant. In one embodiment the third solution is substantially free of a denaturant.
- the applying of the first solution is for 3 to 20 column volumes.
- the applying of the first solution is for 3 to 10 column volumes. In one embodiment the applying of the second solution is for 1 to 10 column volumes.
- the applying of the third solution is for 1 to 10 column volumes.
- the ion exchange chromatography material is in the first step conditioned with a buffered solution.
- This solution is free of, i.e. does not comprise, a denaturant.
- the buffer substance of the conditioning, first buffer solution can be the same or different from the buffer substance of the second solution comprising the polypeptide.
- a second solution comprising the polypeptide is applied to the conditioned ion exchange chromatography material.
- the polypeptide is retained on the ion exchange chromatography material.
- This solution does not comprise a denaturant.
- the buffer substance of the loading, i.e. second, buffer solution can be the same or different from the buffer substance of the third solution.
- a washing, i.e. third, solution can be applied to the loaded ion exchange chromatography material.
- This solution is substantially free of a denaturant.
- a recovering, i.e. fourth, solution comprising one or more denaturants is applied to the chromatography material.
- the method for purifying or obtaining a polypeptide is a column chromatography method.
- the conductivity of the solution in the recovering step is constant.
- the pH-value of the solution in the recovering step is constant.
- the volume applied to the ion exchange chromatography material in the different steps is independently of each other of from 3 to 20 column volumes, in one embodiment of from 4 to 10 column volumes.
- the ion exchange chromatography material is made of polystyrene divinyl benzene derivatized with functional groups.
- the anion exchange chromatography material is a polystyrene divinyl benzene derivatized with quaternized poly ethyleneimine functional groups.
- the cation exchange chromatography material is a polystyrene divinyl benzene derivatized with sulfopropyl functional groups.
- Protein concentration was determined by determining the optical density (OD) at 280 nm, with a reference wavelength of 320 nm, using the molar extinction coefficient calculated on the basis of the amino acid sequence.
- the chromatography was conducted with a Tosoh Haas TSK 3000 SWXL column on an ASI-100 HPLC system (Dionex, Idstein, Germany). The elution peaks were monitored at 280 nm by a UV diode array detector (Dionex). After dissolution of the concentrated samples to 1 mg/ml the column was washed with a buffer consisting of 200 mM potassium dihydrogen phosphate and 250 mM potassium chloride pH 7.0 until a stable baseline was achieved. The analyzing runs were performed under isocratic conditions using a flow rate of 0.5 ml/min. over 30 min. at room temperature. The chromatograms were integrated manually with Chromeleon (Dionex, Idstein, Germany).
- the purity is analyzed by RP-HPLC.
- the assay is performed on a Phenomenex C18 column using an acetonitrile/aqueous TFA gradient.
- the elution profile is monitored as UV absorbance at 215 nm.
- the percentages of the eluted substances are calculated based upon the total peak area of the eluted proteins.
- the walls of the wells of a micro titer plate are coated with a mixture of serum albumin and Streptavidin.
- a goat derived polyclonal antibody against HCP is bound to the walls of the wells of the micro titer plate.
- different wells of the micro titer plate are incubated with a HCP calibration sequence of different concentrations and sample solution. After the incubation not bound sample material is removed by washing with buffer solution.
- the wells are incubated with an antibody peroxidase conjugate to detect bound host cell protein. The fixed peroxidase activity is detected by incubation with ABTS and detection at 405 nm.
- Biotin was bound to a microtiter plate.
- a reaction mixture of streptavidin, single-stranded DNA and biotinylated single-stranded DNA binding protein was added.
- the binding protein was able to bind DNA and was biotinylated. In this manner it was possible to specifically remove the DNA from the sample mixture.
- the streptavidin bound the biotin on the microtiter plate as well as the biotin which was coupled to the single-stranded DNA binding protein.
- a DNA-specific antibody which was coupled to urease was added to this total complex. Addition of urea resulted in a hydrolysis of the urea which caused a local change in the pH. This change can be detected as an altered surface potential. The change in the surface potential was proportional to the amount of bound DNA.
- Single stranded DNA was obtained by proteinase K digestion and denaturation with SDS.
- inclusion bodies e.g. be performed according the method by Rudolph, et al. (Rudolph, R., et al., Folding Proteins, In: Creighton, T.E., (ed.): Protein function: A Practical Approach, Oxford University Press (1997) 57-99).
- the inclusion bodies were stored at ⁇ 70° C. Solubilization of the inclusion bodies can likewise be performed according the method by Rudolph, et al. (Rudolph, R., et al., Folding Proteins, In: Creighton, T.E., (ed.): Protein function: A Practical Approach, Oxford University Press (1997) 57-99).
- the fusion protein cannot be obtained during the wash steps with the urea solution and the 2-propanol solution. Elution can only be effected by using the guanidinium hydrochloride solution.
- the antibody can be obtained.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/920,127 US11332514B2 (en) | 2011-08-25 | 2015-10-22 | Cation and anion exchange chromatography method |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11178745.3 | 2011-08-25 | ||
EP11178745 | 2011-08-25 | ||
EP11183862.9 | 2011-10-04 | ||
EP11183862 | 2011-10-04 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/920,127 Continuation US11332514B2 (en) | 2011-08-25 | 2015-10-22 | Cation and anion exchange chromatography method |
Publications (1)
Publication Number | Publication Date |
---|---|
US20130053551A1 true US20130053551A1 (en) | 2013-02-28 |
Family
ID=46717838
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/588,281 Abandoned US20130053551A1 (en) | 2011-08-25 | 2012-08-17 | Cation and anion exchange chromatography method |
US14/920,127 Active 2034-03-11 US11332514B2 (en) | 2011-08-25 | 2015-10-22 | Cation and anion exchange chromatography method |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/920,127 Active 2034-03-11 US11332514B2 (en) | 2011-08-25 | 2015-10-22 | Cation and anion exchange chromatography method |
Country Status (10)
Country | Link |
---|---|
US (2) | US20130053551A1 (ko) |
EP (1) | EP2748178B1 (ko) |
JP (1) | JP6116565B2 (ko) |
KR (1) | KR20140062044A (ko) |
CN (1) | CN103703015B (ko) |
BR (1) | BR112014004463A2 (ko) |
CA (1) | CA2838814A1 (ko) |
MX (1) | MX2014001918A (ko) |
RU (1) | RU2014108241A (ko) |
WO (1) | WO2013026803A1 (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8791063B2 (en) | 2011-08-25 | 2014-07-29 | Hoffmann-La Roche, Inc. | Shortened tetranectin-apolipoprotein A-I fusion protein, a lipid particle containing it, and uses thereof |
US20210224510A1 (en) * | 2018-07-06 | 2021-07-22 | Universität Zürich | Method and computer program for clustering large multiplexed spatially resolved data of a biological sample |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103980351B (zh) * | 2014-05-27 | 2016-05-18 | 上海第一生化药业有限公司 | 加压素、加压素鞣酸盐的制备方法 |
CN109851667A (zh) * | 2018-12-29 | 2019-06-07 | 江苏万邦医药科技有限公司 | 一种德谷胰岛素前体的纯化方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4129560A (en) * | 1976-07-01 | 1978-12-12 | Hoechst Aktiengesellschaft | Process for the purification of high molecular weight peptides using non-ionic detergents |
WO1989005157A1 (en) * | 1987-12-09 | 1989-06-15 | Invitron Corporation | Efficient large-scale purification of immunoglobulins and derivatives |
US5463029A (en) * | 1992-11-23 | 1995-10-31 | Immunex Corporation | Purification of fusion proteins comprising GM-CSF and IL-3 |
US20030229212A1 (en) * | 2002-04-26 | 2003-12-11 | Robert Fahrner | Non-affinity purification of proteins |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU5397579A (en) | 1978-12-26 | 1980-07-03 | Eli Lilly And Company | Purifying insulin |
DE4118912C1 (ko) | 1991-06-08 | 1992-07-02 | Biotest Pharma Gmbh, 6072 Dreieich, De | |
DE4124896C1 (ko) | 1991-07-26 | 1993-01-21 | Eloma Gmbh Bedarfsartikel Zur Gemeinschaftsverpflegung, 8031 Maisach, De | |
US6451987B1 (en) | 1999-03-15 | 2002-09-17 | Novo Nordisk A/S | Ion exchange chromatography of proteins and peptides |
JP4344136B2 (ja) | 2000-11-10 | 2009-10-14 | エフ・ホフマン−ラ・ロシュ・リミテッド | アポリポタンパク質類似体 |
US20040048315A1 (en) * | 2002-08-28 | 2004-03-11 | Pharmacia Corporation | Method for the preparation of growth hormone and antagonist thereof having lower levels of isoform impurities thereof |
LT1543038T (lt) | 2002-09-11 | 2017-07-10 | Genentech, Inc. | Baltymo gryninimas |
DE60330787D1 (de) * | 2002-09-20 | 2010-02-11 | Pharmacia Corp | Verfahren zur verringerung der aggregatmengen des pegylierten proteins |
GB0224082D0 (en) | 2002-10-16 | 2002-11-27 | Celltech R&D Ltd | Biological products |
AU2007227700A1 (en) * | 2006-03-20 | 2007-09-27 | Medarex, Inc. | Protein purification |
US20090242750A1 (en) * | 2006-06-30 | 2009-10-01 | Ge Healthcare Bio-Sciences Ab | Protein purification and identification |
US8013122B2 (en) * | 2006-12-20 | 2011-09-06 | Kieu Hoang | Method of purifying apolipoprotein A-1 |
CN100586958C (zh) | 2006-12-20 | 2010-02-03 | 上海莱士血液制品股份有限公司 | 高纯度载脂蛋白a-i的制备方法 |
ES2576109T3 (es) * | 2008-12-02 | 2016-07-05 | Novo Nordisk Health Care Ag | Purificación de polipéptidos |
WO2011133191A1 (en) * | 2010-04-23 | 2011-10-27 | Serum Institute Of India, Ltd. | Simple method for simultaneous removal of multiple impurities from culture supernatants to ultralow levels |
AR082163A1 (es) | 2010-07-15 | 2012-11-14 | Hoffmann La Roche | Anticuerpos especificamente ligantes del tslpr humano y metodos de utilizacion de los mismos |
ES2558751T3 (es) | 2010-08-30 | 2016-02-08 | F. Hoffmann-La Roche Ag | Alimento alcalino |
WO2012028523A2 (en) | 2010-08-30 | 2012-03-08 | F. Hoffmann-La Roche Ag | Prokaryotic expression construct |
WO2012028526A2 (en) | 2010-08-30 | 2012-03-08 | F. Hoffmann-La Roche Ag | Tetranectin-apolipoprotein a-i, lipid particles containing it and its use |
RU2013111676A (ru) | 2010-08-30 | 2014-10-10 | Ф. Хоффманн-Ля Рош Аг | Способ получения тетранектин-аполипопротеин а-i частицы, полученная таким образом липидная частица и ее применение |
-
2012
- 2012-08-17 CN CN201280036823.9A patent/CN103703015B/zh active Active
- 2012-08-17 EP EP12748689.2A patent/EP2748178B1/en active Active
- 2012-08-17 JP JP2014526457A patent/JP6116565B2/ja active Active
- 2012-08-17 RU RU2014108241/04A patent/RU2014108241A/ru not_active Application Discontinuation
- 2012-08-17 BR BR112014004463A patent/BR112014004463A2/pt not_active IP Right Cessation
- 2012-08-17 US US13/588,281 patent/US20130053551A1/en not_active Abandoned
- 2012-08-17 KR KR1020147004660A patent/KR20140062044A/ko not_active Application Discontinuation
- 2012-08-17 WO PCT/EP2012/066135 patent/WO2013026803A1/en active Application Filing
- 2012-08-17 CA CA2838814A patent/CA2838814A1/en not_active Abandoned
- 2012-08-17 MX MX2014001918A patent/MX2014001918A/es unknown
-
2015
- 2015-10-22 US US14/920,127 patent/US11332514B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4129560A (en) * | 1976-07-01 | 1978-12-12 | Hoechst Aktiengesellschaft | Process for the purification of high molecular weight peptides using non-ionic detergents |
WO1989005157A1 (en) * | 1987-12-09 | 1989-06-15 | Invitron Corporation | Efficient large-scale purification of immunoglobulins and derivatives |
US5463029A (en) * | 1992-11-23 | 1995-10-31 | Immunex Corporation | Purification of fusion proteins comprising GM-CSF and IL-3 |
US20030229212A1 (en) * | 2002-04-26 | 2003-12-11 | Robert Fahrner | Non-affinity purification of proteins |
Non-Patent Citations (14)
Title |
---|
Chromedia, screen shot of http://www.chromedia.org/chromedia?waxtrapp=zjmmmEsHonOvmOlIEwCcDmK, 2015. * |
Gu et al., Urea gradient size-exclusion chromatography enhanced the yield of lysozyme refolding, J. Chromatog. A, 918 (2001) 311-318 * |
Ion Exchange section, pages 737-783 of Vol. 14 of Encyclopedia of Chemical Technology, John Wiley & Sons, 1995 * |
Khademi et al., Effect of urea on protein separation by ion-exchange chromatography, J. Biochem. 2010;147(5):735-741 (published online 2/4/2010) * |
Kolk & Samuel, Isolation, Chemical and Immunological Characterization of Two Strongly Basic Nuclear Proteins from Human Spermatozoa, Biochimica et Biophysica Acta, 393 (1975) 307-319 * |
Lim et al., Urea, but not guanidiums, destabilizes proteins by forming hydrogen bonds to the peptide group, PNAS 2/24/09, vol. 10-6, no. 8, 2595-2600 * |
Lin & Bai, Refolding of reduced/denatured bovine pancreatic insulin with ion-exchange chromatography coupled with MALDI-TOF MS, Chinese Chemical Letters 20 (2009) 1487-1490 * |
MSDS of Bio-Rad70, 2015 * |
MSDS of Guanidine Hydrochloride, MSDS No: G8371, Mallinckrodt Baker, Inc., 1996, 4 pages * |
Norburg, A cation-exchange material for protein separations based on grafting of thiol-terminated sulfopropyl methacrylate telomers onto hydrophilized monodisperse divinylbenzene particles, Abstract, J. Separation Science, 31(12):2143-2150 * |
Protein sequence of Homo sapiens proapolipoprotein, reference gb|AAA51747.1. * |
Singh & Panda, Solubilization and refolding of bacterial inclusion body proteins, Journal of Bioscience and Bioengineering, Volume 99, Issue 4, April 2005, Pages 303-310 * |
Wang and Cheng, Urea-Gradient Protein Refolding in Size Exclusion Chromatography, Curr. Pharm. Biotech., 2010, 11, 289-292 * |
Wang et al., On-column refolding of consensus interferon at high concentration with guanidine-hydrochloride and polyethylene glycol gradients, J. Chromatog. A, 1115 (2006) pp. 72-80 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8791063B2 (en) | 2011-08-25 | 2014-07-29 | Hoffmann-La Roche, Inc. | Shortened tetranectin-apolipoprotein A-I fusion protein, a lipid particle containing it, and uses thereof |
US9139640B2 (en) | 2011-08-25 | 2015-09-22 | Hoffmann-La Roche Inc. | Shortened tetranectin-apolipoprotein A-1 fusion protein, a lipid particle containing it, and uses thereof |
US20210224510A1 (en) * | 2018-07-06 | 2021-07-22 | Universität Zürich | Method and computer program for clustering large multiplexed spatially resolved data of a biological sample |
US11989959B2 (en) * | 2018-07-06 | 2024-05-21 | Universität Zürich | Method and computer program for clustering large multiplexed spatially resolved data of a biological sample |
Also Published As
Publication number | Publication date |
---|---|
US11332514B2 (en) | 2022-05-17 |
EP2748178A1 (en) | 2014-07-02 |
KR20140062044A (ko) | 2014-05-22 |
BR112014004463A2 (pt) | 2017-03-28 |
CA2838814A1 (en) | 2013-02-28 |
MX2014001918A (es) | 2014-04-14 |
EP2748178B1 (en) | 2018-10-31 |
US20160237140A1 (en) | 2016-08-18 |
JP6116565B2 (ja) | 2017-04-19 |
RU2014108241A (ru) | 2015-09-27 |
CN103703015B (zh) | 2019-07-05 |
WO2013026803A1 (en) | 2013-02-28 |
JP2014524453A (ja) | 2014-09-22 |
CN103703015A (zh) | 2014-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200165297A1 (en) | Optimized method for antibody capturing by mixed mode chromatography | |
ES2449148T5 (es) | Purificación de inmunoglobulinas | |
US9481706B2 (en) | Purification of non-glycosylated polypeptides | |
US11332514B2 (en) | Cation and anion exchange chromatography method | |
EP2773439A1 (en) | Chromatography process for resolving heterogeneous antibody aggregates | |
US8796419B2 (en) | Hydrophobic interaction chromatography method | |
US20090264630A1 (en) | Method of separating monomeric protein(s) | |
CA3057286A1 (en) | A process for the purification of recombinant antibody fragments | |
Musienko et al. | Research report Purification of human IgG and lysozyme refolding |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: F.HOFFMANN-LA ROCHE AG, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ROCHE DIAGNOSTICS GMBH;REEL/FRAME:029210/0299 Effective date: 20121001 Owner name: ROCHE DIAGNOSTICS GMBH, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FALKENSTEIN, ROBERTO;MAGRI, MARIA LAURA;MEHR, MICHAELA;AND OTHERS;REEL/FRAME:029210/0248 Effective date: 20120927 |
|
AS | Assignment |
Owner name: HOFFMANN-LA ROCHE INC., NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:F. HOFFMANN-LA ROCHE AG;REEL/FRAME:029266/0951 Effective date: 20121031 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |